Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Wednesday, 12 September 2012
AstraZeneca wins prestigious business development award AstraZeneca won the award for Best Pharma BD&L Team at the Oxford Bioscience Network’s Annual Awards Dinner last night at The Ashmolean Museum, Oxford, UK.
Monday, 13 August 2012
AstraZeneca and Pfizer enter agreement for over-the-counter NEXIUM; AstraZeneca raises 2012 guidance NEXIUM 20mg retail launch targeted for 2014, subject to regulatory approval.
Thursday, 9 August 2012
AstraZeneca and Bristol-Myers Squibb complete expansion of diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals AstraZeneca and Bristol-Myers Squibb today announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb. As previously disclosed, the payment is being made in connection with the expansion of the diabetes alliance between AstraZeneca and Bristol-Myers Squibb to incorporate the development and marketing of Amylin’s portfolio of diabetes products, and profits and losses arising from the collaboration will be shared equally.
Download our brochure

Download your comprehensive guide to partnering with us.

Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar